Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma-Reference-Cited by-同舟云学术

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Published:2017-06-06 Issue:9 Volume:7 Page:984-998
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Kondrashova Olga,Nguyen Minh,Shield-Artin Kristy,Tinker Anna V.,Teng Nelson N.H.,Harrell Maria I.,Kuiper Michael J.,Ho Gwo-Yaw,Barker Holly,Jasin Maria,Prakash Rohit,Kass Elizabeth M.,Sullivan Meghan R.,Brunette Gregory J.,Bernstein Kara A.,Coleman Robert L.,Floquet Anne,Friedlander Michael,Kichenadasse Ganessan,O'Malley David M.,Oza Amit,Sun James,Robillard Liliane,Maloney Lara,Bowtell David,Giordano Heidi,Wakefield Matthew J.,Kaufmann Scott H.,Simmons Andrew D.,Harding Thomas C.,Raponi Mitch,McNeish Iain A.,Swisher Elizabeth M.,Lin Kevin K.,Scott Clare L.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 332 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition;Radiotherapy and Oncology;2024-11

2. Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance;Gynecologic Oncology Reports;2024-10

3. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes;Expert Review of Anticancer Therapy;2024-09-03

4. NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy;Cell Death & Disease;2024-08-26

5. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches;Frontiers in Oncology;2024-08-16